



















Background: the revised 
recommendation
The German Standing Committee on 
Vaccination (Ständige Impfkommission, 
STIKO) has revised its recommendation 
for hepatitis B vaccination of persons at 
particular risk and for hepatitis B postex-
posure prophylaxis according to its Stan-
dard Operating Procedure (SOP) for the 
development of evidence-based vaccina-
tion recommendations [1]. In abbreviated 




F		STIKO recommends vaccination of 
the following three indication groups 
(in addition to a recommendation for 
at-risk travellers):
1	Indication group 1: Persons at risk of 
severe hepatitis B due to existing or 
expected immunodeficiency or sup-
pression or due to other preexist-
ing diseases
1	Indication group 2: Persons at in-
creased risk of non-occupational 
exposure
1	Indication group 3: Persons at in-
creased risk of occupational expo-
sure
Relevant examples are given for each in-
dication group.
F		STIKO recommends hepatitis B vac-
cination of these risk groups, without 
prior routine serological testing, ex-
cept in special situations.
F		For all groups, STIKO recommends 
assessing vaccination success by anti-
HBs testing 4–8 weeks after the third 
vaccine dose. An anti-HBs level of 
≥100 IU/l is considered indicative of 
successful vaccination against hepati-
tis B.
F		For low-responders (anti-HBs 10–
99 IU/l), STIKO recommends vac-
cination with one additional vaccine 
dose, followed by anti-HBs testing. If 
anti-HBs is still <100 IU/l, two more 
doses should be administered. Con-
troversy exists as to which approach 
should be followed if anti-HBs is still 
<100 IU/l after six doses of hepatitis B 
vaccine.
F		For non-responders (anti-HBs 
<10 IU/l), STIKO recommends test-
ing for HBsAg and anti-HBc to ex-
clude chronic infection. If both pa-
rameters are negative, the recommen-
dations for low-responders should be 
followed.
F		STIKO does not recommend rou-
tine booster immunizations after suc-
cessful primary vaccination (anti-HBs 
≥100 IU/l). Exceptions are made in 
patients with humoral immune defi-
ciency for whom annual testing of an-
ti-HBs (and booster immunization if 
anti-HBs <100 IU/l) is recommend-
ed, as well as in persons who are at 
particularly high individual exposure 
risk (anti-HBs testing after 10 years; 









F		For persons who were vaccinated 
against hepatitis B during infancy and 
who later enter one of the risk groups, 
STIKO recommends vaccination with 
one dose of hepatitis B vaccine, fol-
lowed by anti-HBs testing.
Postexposure prophylaxis 
against hepatitis B
F		STIKO recommends assessing the 
HBsAg status of the index patient 
(i.e., the “donor”). If the donor is 
 HBsAg positive or if HBsAg status of 
the donor cannot be assessed, post-
exposure prophylaxis is recommend-
ed according to the vaccination status 
of the exposed person.
F		In fully vaccinated exposed persons, 
management depends on the result of 
the most recent anti-HBs test result. 
Persons with anti-HBs ≥100 IU/l test-
ed within the last 10 years are consid-
ered fully protected. All others should 
receive postexposure prophylaxis de-
pending on the current and most re-
cent anti-HBs levels.
F		In incompletely vaccinated exposed 
persons, the current anti-HBs level 
should be determined. Further man-
agement depends on the current and 
most recent anti-HBs levels. Further-
more, the vaccination series should be 
completed.
F		In unvaccinated persons, anti-HBs, 
HBsAg, and anti-HBc should be de-
termined to decide on further proce-
dures.
For the full text of the STIKO recommen-
dation, see http://www.stiko.de (in Ger-
man).
This paper reports the scientific evi-
dence on which the revision of STIKO’s 
previous recommendations is based.
Introduction
The aim of the revision was to adapt the 
recommendations for hepatitis B vaccina-
tion of persons at particular risk and for 
postexposure prophylaxis to bring them 
in line with the current state of knowledge 
and to increase their feasibility. The revi-
sion does not affect the recommendations 
for standard vaccination against hepati-
tis B during the first year of life, which re-
mains unchanged (see http://www.stiko.
de).
Following the methodology of STIKO, 
the recommendation was adapted after 
conducting orientating and systematic 
literature searches on the following ques-
tions:
1.  Which population subgroups are at 
increased risk of hepatitis B infection 
or complications?
2.  What is the duration of protection 
against hepatitis B after primary vac-
cination?
3.  Does duration of protection depend 
on the level of anti-HBs after primary 
vaccination?
The results of these searches, which are 
summarized below, were used to revise 
the classification of risk groups and the 
guidance on serological testing, boost-
er immunization as well as postexposure 
prophylaxis.
The goal of hepatitis B 
vaccination
The goal of vaccination against hepati-
tis B is to prevent acute clinical hepatitis 
and chronic infection by the hepatitis B 
virus (HBV) in Germany. Beyond that, all 
types of HBV infection (including occult 
infections) should be prevented.
Hepatitis B: virus, disease, 
and vaccination
Hepatitis B is inflammation of the liv-
er caused by HBV, a virus that occurs 
worldwide. It is transmitted sexually and 
through exposure to infectious blood or 
body fluids. The majority of infected im-
munocompetent adults recover spontane-
ously from disease. However, in 5%–10% 
of infected patients, disease progresses to-
wards chronic infection, which can result 
in liver cirrhosis and liver cancer. Chronic 
disease is more common in children and 
immunocompromised individuals [2]. 
According to §6 of the German Protection 
against Infection Act (Infektionsschutz­
gesetz, IfSG) acute hepatitis B has been a 
notifiable disease in Germany since 2001.
Vaccination against hepatitis B has 
been recommended for all infants in Ger-
many since 1995. Furthermore, it is rec-
ommended for persons at increased risk 
for hepatitis B infection. In infants, prima-
ry vaccination consists of at least three in-
tramuscular doses of hepatitis B vaccine, 
which should be administered preferably 
on a 3-(4) dose schedule at ages 2, (3), 4, 
and 12 months. After the age of 12 months, 
a three-dose schedule (0, 1, 6 months) is 
recommended. Two single antigen vac-
cines are available in Germany, Engerix 
B® (GSK) and Recombivax HB® (Mer-
ck); additionally, an adjuvant containing 
a single formulation vaccine, Fendrix® 
(GSK), is available. Combination vac-
cines used for the vaccination of infants 
and children in Germany include Infanrix 
hexa® (GSK) and Heyxon® (Sanofi Pasteur 
MSD); Twinrix® (GSK) is used for the vac-
cination of adults. All these vaccines con-
tain HBsAg produced by DNA recombi-
nant technology and expressed in yeasts.
Epidemiology of 
hepatitis B in Germany
In 2012, 1670 cases of hepatitis B were re-
ported to the Robert Koch Institute (RKI), 
of which 679 met the reference case defini-
tion. Compared to 2011 (812 cases accord-
ing to the reference case definition), the 
number of cases decreased by 16% [3]. In 
2012, the incidence of reported acute hep-
atitis B in Germany was 0.8 per 100,000 
residents, with men (1.2 per 100,000) be-
ing more frequently affected than women 
(0.5 per 100,000). Incidence was highest 
in men and women aged 30–39 years (2.0 
per 100,000 and 0.9 per 100,000, respec-
tively). Only six cases in children and ado-
lescents below 15 years of age were report-
ed to RKI in 2012, equalling the median 
of the past 5 years. As compared to 2001–
2005 (median: 41 cases), the number of 
cases has declined, most likely due to the 
introduction in 1995 of standard immu-
nization against hepatitis B for all infants.
As far as can be concluded from the 
notification data from 2012, sexual trans-
mission was the most prevalent mode of 
infection, followed by household contact 
with an HBV carrier, intravenous (i.v.) 
drug use, and hemodialysis. Of 525 acute 
HBV cases with information on vaccina-
tion status available, 494 (94%) cases were 
not vaccinated against hepatitis B.
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It should be borne in mind that, due to 
mild or asymptomatic infections [4], the 
true number of acute hepatitis B infec-
tions is likely to be underestimated.
Classification of risk 
groups for hepatitis B
Due to occupational exposure, risk behav-
ior or other non-occupational exposure or 
preexisting diseases, some subgroups are 
likely to be at increased risk of HBV in-
fection, or are at increased risk of compli-
cations and chronification in the case of 
infection. In addition to the routine rec-
ommendation of vaccination of all in-
fants, STIKO therefore recommends vac-
cinating these risk groups against hepati-
tis B to protect them against infection and 
to prevent transmission.
In the previous version of the recom-
mendation, vaccination against hepati-
tis B was recommended for eight indica-
tion groups [5]. For the revised recom-
mendation, these were re-classified into 
three groups, supplemented by a recom-
mendation for at-risk travelers. Examples 
are provided for each of the three groups. 
STIKO emphasizes that these examples 
should serve merely for orientation and 
that they are not intended to represent 
a definitive list of indication groups for 
vaccination against hepatitis B. In partic-
ular, STIKO emphasizes that an individual 
risk assessment is mandatory, since some 
of the indication groups include individ-
uals with varying risk of exposure. Fur-
thermore, STIKO underlines that the ab-
sence of person groups in the revised rec-
ommendation who were explicitly men-
tioned in the previous version does not 
mean that these persons should not be 
vaccinated. Instead, the individual risk of 
these persons should be assessed to assign 
them to one of the new indication groups.
By orientating the literature search 
(search terms: hepatitis B; epidemiolo-
gy; prevalence; Europe; e.g., HIV, drug 
use, hemodialysis etc), it was verified that 
the examples of groups of persons named 
are either at increased risk of exposure to 
HBV or are at increased risk of severe dis-
ease due to HBV infection. In the follow-
ing, relevant references are given for each 
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F		Indication group 1: Persons at risk of 
severe hepatitis B due to existing or 
expected immunodeficiency or –sup-
pression or due to other preexisting 
diseases.Examples: HIV-positive indi-
viduals, hepatitis C-positive persons 
[6, 7], patients on hemodialysis [8, 9, 
10].
F		Indication group 2: Persons at in-
creased risk of non-occupational ex-
posure.Examples: Persons living to-
gether with HBsAg carriers [11, 12, 
13], persons at high risk of acquiring 
hepatitis B by sexual contact [11, 14, 
15], people who inject drugs [14, 16, 
17], prison inmates [18, 19, 20], psy-
chiatric inpatients [21, 22].
F		Indication group 3: Persons at in-
creased risk of occupational expo-
sure.Examples: Health care personnel 
(HCP) at risk of exposure (including 
trainees, laboratory personnel, clean-
ing personnel) [23, 24, 25], first aid-
ers [26, 27], police officers [29], per-
sonnel of facilities where an increased 
prevalence of HBV-infected persons 
is likely to be present (e.g., correction-
al facilities, asylum seeker shelters, 
homes for the handicapped) [18, 19, 
20, 27, 28, 29].
Duration of protection 
after primary vaccination 
against hepatitis B
A systematic literature review was con-
ducted on the duration of protection 
against hepatitis B after successful prima-
ry vaccination at the age of ≥1 year. The re-
view aimed at identifying long-term stud-
ies that investigated the incidence of hepa-
titis B breakthrough infections in persons 
who had received primary vaccination 
without subsequent booster vaccinations. 
“Breakthrough infection” but not the level 
of anti-HBs during follow-up was defined 
as the primary outcome, since loss of mea-
surable anti-HBs after successful primary 
vaccination does not indicate a loss of pro-
tection against hepatitis B infection, prob-
ably due to immunological memory [30]. 
Therefore, only the presence of a break-
through infection definitely indicates loss 
of protection against HBV.
The evidence assessment process 
was conducted according to the SOP of 
STIKO for the systematic development 
of vaccination recommendations [1]. Fol-
lowing the methodology of the GRADE 
Working Group [31], patient-relevant out-
comes were defined and rated regarding 
their importance for decision-making.
The following outcomes, which are in-
dicators for breakthrough infections after 
successful primary vaccination, were rat-
ed as “critical” or “important”:
CRITICAL:
F		Death due to hepatitis B







Taking these outcomes into consideration, 
a systematic review of the published liter-
ature was conducted using the databas-
es MEDLINE, EMBASE, SciSearch, Co-
chrane Central Register of Controlled 
Trials, and Cochrane Database of System-
atic Reviews (search terms: “hepatitis B”; 
Tab. 1  Literature data on groups of persons belonging to indication group 1: persons at risk of severe hepatitis B due to existing or expected 
 immunodeficiency or –suppression or due to other preexisting diseases
































































































































































“vaccin*”; “immunization”; “random*”; 
“blind*”; “placebo”; “meta-analys*”; “co-
hort”; “time series”; “case-control”; “eco-
logical”; “cross-sectional”). Additionally, 
the results of four Cochrane Reviews [32, 
33, 34, 35] and one meta-analysis [36] rel-
evant to the topic were considered.
The literature search yielded 3924 publica-
tions. Studies meeting the following inclu-
sion criteria were included:
1.  Randomized controlled trial (RCT) 
or observational study (all study de-
signs)
2.  Age at start of primary vaccination: 
≥1 year
3.  No previous hepatitis B infection 
(proven by serological testing)
4.  Vaccination with a hepatitis B vac-
cine according to the schedule 0-1-6(-
12) months
5.  Success of vaccination evaluated and 
reported (proven by anti-HBs testing)
6.  No booster vaccinations during fol-
low-up
7.  Duration of follow-up ≥5 years
8.  At least one of the above-mentioned 
important or critical outcomes was 
investigated.
Application of the inclusion criteria led 
to the identification of one RCT [37] and 
nine observational studies ([38, 39, 40, 41, 
42, 43, 44, 45, 46], see .	Fig. 1).
The results of the systematic literature 
review are reported below in detail, as well 
as an assessment of the quality of evidence 
according to GRADE, where applicable. 
Due to the heterogeneity in study designs 
and results, a meta-analysis with statisti-
cal pooling of results was not performed.
Randomized controlled trials
The only RCT meeting all inclusion cri-
teria [37] was performed in China, us-
ing a plasma-derived vaccine and includ-
ing 649 participants (vaccine group: 308, 
placebo group: 341; age at vaccination: 
14 months). Successful vaccination was 
defined as anti-HBs ≥10 IU/l after pri-
mary vaccination. Participants were fol-
lowed-up for a period of 15 years, during 
which the majority of participants left the 
study (vaccine group: 83%, placebo group: 
72%). At 15 years following primary vac-
cination, vaccine efficacy was 96% [95% 
confidence interval (CI): 74–99%] against 
chronic hepatitis B, 89% (95% CI: 12–
99%) against HBsAg positivity, and 73% 
(95% CI: 57–84%) against isolated anti-
HBc positivity.
Based on these data, the quality of ev-
idence was assessed using the GRADE 
methodology and results summarized 
in a GRADE evidence profile (.	Tab. 4). 
High loss-to-follow-up rates, which dif-
fered between vaccine and placebo 
groups, were considered to indicate high 
risk of bias. Evidence was classified as “in-
direct” considering the nature of the vac-
cine used in the study (plasma-derived). 
Because the study was conducted in a re-
gion with a high HBsAg carrier preva-
lence (China), which could have resulted 
in natural boosting of study participants, 
evidence was further downgraded for 
indirectness. In summary, there is very 
low quality evidence (i.e., very low con-
fidence in the effect estimate) that suc-
cessful primary vaccination against hep-
atitis B (indicated by anti-HBs ≥10 IU/l) 
protects against hepatitis B over a period 
of 15 years with the above-mentioned ef-
ficacy data.
Observational studies
All nine observational studies were single-
armed cohort studies [38, 40, 41, 42, 45, 
46] or arms of former RCTs which were 
continued as cohort studies [39, 43, 44]. 
None of the studies included a non-vacci-
nated control group. In seven out of nine 
cohort studies, successful vaccination was 
defined as anti-HBs ≥10 IU/l after prima-
ry vaccination [38, 39, 40, 41, 43, 45, 46]. 
In the remaining two studies, results were 
stratified according to anti-HBs levels af-
ter primary vaccination (10–99 IU/l vs. 
≥100 IU/l) [42, 44].
Study characteristics of the seven sin-
gle-armed cohort studies, in which vac-
cination success was defined as anti-HBs 
≥10 IU/l, are shown in .	Tab. 5. The 
study by But et al. [39] was divided into 
two sub-studies, since participants were 
vaccinated with either a plasma-derived 
or a recombinant vaccine. Duration of fol-
low-up in the seven studies ranged from 
5 to 22 years. Cases of clinical hepatitis B 
or HBsAg positivity were not observed in 
any of the studies. Cases of isolated anti-
HBc positivity were found in five studies, 
suggesting breakthrough infection [4]. 
These occurred in 1.7%–26% of partici-
pants, mainly in countries with a moder-
ate or high prevalence of HBsAg carriers 
(e.g., China, India, Iran).
In terms of HBV exposure risk and 
vaccination, two of the seven cohort study 
settings were considered to be comparable 
to Germany. In the Canadian study per-
formed by Gilca et al. [43], 326 children 
aged 8–10 years were vaccinated with a 
recombinant vaccine (Engerix B®, GSK) 
and followed-up over a period of 10 years, 
during which 15% of the participants left 
the study. No cases with HBsAg positivi-
ty or isolated anti-HBc positivity were ob-
served during the entire follow-up period. 
The Belgian study by Van Herck et al. [46] 
included 188 adult participants (mean age 
at vaccination: 23.3±0.28 years) who were 
vaccinated with a recombinant vaccine 
(not further specified) and were followed-
up for a period of 8 years. Of these par-
ticipants, 79% were lost to follow-up. No 
cases of HBsAg positivity or isolated an-
3,924 articles potentially eligible 
225 abstracts screened
108 articles screened as full text
10 studies included
3,699 irrelevant articles excluded
117 irrelevant articles excluded














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ti-HBc positivity were observed in the re-
maining participants. No cases of acute or 
chronic hepatitis B were reported in either 
publication [43, 46].
An observational study published by 
Zanetti et al. [47] was considered to pro-
vide additional evidence. Although this 
study did not meet all inclusion criteria of 
the systematic review (lack of a definition 
of vaccination success in the publication), 
it was considered informative in terms of 
the investigated population, length of fol-
low-up period, and included parameters. 
This was a retrospective cohort study per-
formed in Italy which included 446 male 
army recruits. Participants were vaccinat-
ed during childhood with a recombinant 
vaccine (Engerix B®, GSK), had not re-
ceived booster vaccinations, and were re-
investigated 10 years after primary vacci-
nation. No cases of HBsAg positivity were 
observed. Isolated anti-HBc positivity 
was detected in 0.9% of the participants. 
None of the participants was positive for 
HBV DNA.
The quality of evidence from the sin-
gle-armed cohort studies cannot be as-
sessed by the GRADE methodology be-
cause all studies lacked a non-vaccinated 
comparison group. Taken together, these 
studies show that no cases with clinical 
hepatitis or HBsAg positivity occurred 
during a 10-year follow-up period in set-
tings comparable to Germany (low prev-
alence of HBsAg carriers; use of recombi-
nant vaccines) when vaccination success 
was defined as anti-HBs ≥10 IU/l. How-
ever, the small numbers of participants in 
the studies need to be considered: Given 
the low incidence of hepatitis B in Germa-
ny, very large and long-term prospective 
cohort studies would have been needed 
to detect breakthrough infections even if 
vaccine effectiveness was low. In the stud-
ies from Europe and North America, less 
than 1% of vaccinated participants showed 
isolated anti-HBc positivity during the 
follow-up period.
Anti-HBs threshold for  
the definition of 
vaccination success
In order to address the question of wheth-
er duration of protection depends on the 
level of anti-HBs after primary vaccina-
tion, studies stratifying results accord-
ing to the anti-HBs level were analyzed. 
Such data were available from two co-
hort studies conducted in Canada [42] 
and the US [44]. Duval et al. [42] includ-
ed 328 participants who originated from 
a study arm of a randomized controlled 
trial. Participants were 8–10 years old at 
the time of primary vaccination with a 
recombinant vaccine (Recombivax-HB®, 
Merck) and were followed-up over a pe-
riod of 5 years. In all, 17% of the partici-
pants left the study during follow-up. By 
the end of the study, no cases of clinical 
hepatitis B, HBsAg positivity, or isolated 
anti-HBc positivity were observed, either 
in participants who had anti-HBs levels 
of 10–99 IU/l after primary vaccination 
(n=7) or in those who had anti-HBs lev-
els of ≥100 IU/l (n=268).
The study by Hadler et al. [44] includ-
ed 773 participants who originated from 
the vaccinated study arm of an RCT in 
homosexual men. At primary vaccina-
tion, participants were 29.7±7.6 years old. 
Study participants were vaccinated with 
a plasma-derived vaccine (Merck) and 
were followed-up for 5 years. Due to un-
clear reporting, the proportion of partic-
ipants who were lost to follow-up could 
not be calculated. Study results for the 
outcomes “HBsAg positivity” and “iso-
lated anti-HBc positivity” were stratified 
according to anti-HBs level after prima-
ry vaccination, measured in sample ra-
tio units (SRU). Incidence of isolated an-
ti-HBc positivity was significantly lower 
in participants with anti-HBs ≥100 SRU 
(425 participants), as compared to those 
who had an anti-HBs of 10–99 SRU 
(210 participants) after vaccination [rel-
ative risk (RR): 0.14; 95% CI: 0.06–0.30]. 
This was accompanied by a non-signifi-
cantly lower incidence of HBsAg positivi-
ty (RR: 0.49; 95% CI: 0.03–7.86) in the for-
mer group.
For the following reasons, the findings 
of this study need to be interpreted with 
caution: In addition to the use of a plas-
ma-derived vaccine, the study popula-
tion experienced a high level of HBV ex-
posure, as shown by a prevalence of HB-
sAg positivity of 13% in the study popula-
tion prior to implementation of the vacci-
nation, indicating a high chance of natural 
boosting. Furthermore, the lost-to-follow-
up rate was unclear. Finally, the SRUs used 



















Alavian et al. [38] 113 32 Iran Health care personnel Recombinant 16 43 26
But et al. (I) [39] 17 5.6 China Children Recombinant 22 84 5.9
But et al. (II) [39] 21 5.3 China Children Plasma-derived  22 80 4.8
Chadha et al. [40] 30 37 India Laboratory personnel Recombinant 10 12 0
Durlach et al. [41] 114 37 Argentina Hospital personnel Recombinant 10 57 1.7
Gilca et al. [43] 276 9 Canada School children Recombinant 10 15 0
Mintai et al. [45] 95 14 China Children Plasma-derived 5 0 9.5
Van Herck et al. 
[46]





























































































































































































































































































































































































































































































































































































































































































































































































































linearly related to the currently used unit 
of measurement (IU/l), particularly in the 
upper measurement range of the assays.
According to GRADE criteria, there is 
evidence of very low quality (i.e., very low 
confidence in the effect estimate) that the 
use of anti-HBs ≥100 IU/l to define suc-
cessful vaccination leads to a lower fre-
quency of breakthrough infections (mea-
sured as anti-HBc positivity) during long-
term follow-up (duration: 5 years) than 
the use of anti-HBs ≥10 IU/l (.	Tab. 6).
Synopsis and interpretation 
of the evidence
The available evidence is considered suf-
ficient by a number of international com-
mittees and expert panels to presume 
long-term or even life-long protection 
against hepatitis B after primary vaccina-
tion (without booster doses) if the vaccin-
ee’s anti-HBs level is ≥10 IU/l 4–8 weeks 
after vaccination [48, 49, 50, 51].
However, STIKO emphasizes that a 
synoptic appraisal of the evidence should 
also consider the diagnostic quality of an-
ti-HBs assays. In a study by Huzly et al. 
[52], nine commercially available assays 
that are used to quantify anti-HBs were 
analyzed. This study detected consider-
able variation in test results when ana-
lyzing identical specimens, resulting in a 
variation coefficient of 47%. Huzly et al. 
concluded that no investigated assay was 
able to provide reliable and reproducible 
results in the range 5–20 IU/l. Accord-
ingly, the authors consider an anti-HBs of 
≥10 IU/l an unreliable threshold to define 
successful vaccination.
In conclusion, STIKO considers an 
anti-HBs level of ≥100 IU/l indicative of 
successful vaccination against hepatitis B. 
This threshold is also recommended by 
other National Immunization Technical 
Advisory Groups (NITAGs) in Europe 
[53, 54, 55]. Since the response to hepati-
tis B vaccination is influenced by a variety 
of factors such as age, body weight, smok-
ing behavior, immune status, and genet-
ics [56, 57, 58, 59, 60], vaccination success 
should be demonstrated by testing for an-
ti-HBs in all persons at particular risk vac-
cinated against hepatitis B.
Controversies exist as to how to man-
age individuals who remain low respond-
ers or non-responders even after two com-
pleted vaccination series (total of six dos-
es), i.e., who continue to show anti-HBs 
levels of 10–99 IU/l or <10 IU/l. While 
CDC’s Advisory Committee on Immu-
nization Practices (ACIP) does not rec-
ommend further vaccine doses [50], oth-
ers have described that up to 14 doses are 
needed to achieve successful vaccination 
in such cases [61]. Since it is unclear which 
approach is appropriate, STIKO only 
names these alternatives without making 
a recommendation.
Given the epidemiological situation 
in Germany, STIKO infers from the ev-
idence reviewed above that, in general, 
no further booster immunizations are 
needed after successful primary vacci-
nation against hepatitis B in childhood 
or adulthood. This conclusion has also 
been drawn by other international pub-
lic health agencies and expert panels. 
The World Health Organization (WHO) 
states that no evidence exists that booster 
immunizations are needed after routine 
vaccination against hepatitis B [49]. This 
position is shared by the US Centers for 
Disease Control and Prevention (CDC) 
[50], the Canadian National Advisory 
Committee on Immunization [62], the 
European Consensus Group on Hepati-
tis B Immunity [48], and the Viral Hepa-
titis Prevention Board [63].
A special situation exists in patients 
with humoral immune deficiency who 
show a rapid decline in anti-HBs levels 
[64, 65]. Annual testing of anti-HBs lev-
els is recommended by STIKO in these pa-
tients (e.g., individuals on hemodialysis).
Furthermore, STIKO assumes that 
certain individuals in each indication 
group have a particularly high individu-
al exposure risk, e.g., persons who are in 
permanent or repeated intimate contact 
with HBsAg carriers or to the mentioned 
groups. These persons are at a high cumu-
lative risk of HBV infection, while waning 
of immunity cannot be completely ruled 
out. Therefore, following a conservative 
approach, STIKO recommends that these 
persons should be tested for anti-HBs af-
ter 10 years, followed by booster vaccina-
tion if anti-HBs is <100 IU/l. Likewise, in 
case of postexposure prophylaxis, a dura-
tion of protection of 10 years after prima-
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